Lpath Inc., of San Diego, completed enrollment of its clinical trial evaluating Isonep in patients with wet age-related macular degeneration. The multicenter phase II trial enrolled patients who have not responded well to existing anti-vascular endothelial growth factor therapies including, Lucentis (ranibizumab, Genentech Inc./Roche AG), Avastin (bevacizumab, Genentech Inc./Roche AG) and Eylea (aflibercept, Regeneron Pharmaceuticals Inc./Bayer AG).